Retatrutide: What Lilly's Trials Show vs. What Gray-Market Users Report

Retatrutide has produced the largest average weight loss of any obesity drug tested in Phase 3, and it is not approved anywhere. Lilly plans to file with FDA in Q1 2027; until then, the only legal way to take it is inside a Lilly trial (Lilly, July 2026).

Demand has not waited. By April 2026, U.S. search interest for retatrutide had reached more than three-quarters of semaglutide's, and FDA data cited by University of Pennsylvania researchers suggest hundreds of thousands of doses entered the U.S. between January and April 2026 (Sehgal et al., medRxiv 2026). Most of it is sold online as "research use only" powder.

So two bodies of evidence now exist. One is Lilly's randomized, placebo-controlled program of more than 5,800 participants. The other is tens of thousands of posts from people injecting gray-market vials. They do not describe the same experience, and the reasons why matter to anyone thinking about trying it.

What retatrutide is

Retatrutide is a single once-weekly injectable peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. Semaglutide hits one of these; tirzepatide hits two. The glucagon arm is the new piece, and it is expected to raise energy expenditure and reduce liver fat.

Lilly states plainly that it is an investigational molecule that cannot be legally sold or marketed for human use. It is also a long, modified peptide that Lilly is filing as a biologic (BLA), with its manufacturing (CMC) package still being completed (Lilly, July 2026). Whether it should be regulated as a biologic or a drug is itself under legal dispute (AJMC, Aug 2026).

What Lilly's trials show

In controlled trials, retatrutide 12 mg produced 21–28% average weight loss at 80 weeks, with mostly gastrointestinal side effects and a new nerve-sensation signal. These are Lilly's topline numbers; full peer-reviewed papers for most Phase 3 trials are still pending.

Weight loss figures are Lilly's efficacy estimand, which assumes everyone stayed on drug. Counting people who stopped, TRIUMPH-1's 12 mg arm averaged 25.0%. In a 104-week extension for participants with BMI ≥35, the 12 mg group reached 30.3%. Earlier, TRIUMPH-4 in knee osteoarthritis reported 28.7% at 68 weeks (Pharmaceutical Journal), and the 2023 Phase 2 trial reported 24.2% at 48 weeks (Jastreboff et al., NEJM).

Side effects in trials. Gastrointestinal effects dominated. In TRIUMPH-1 at 12 mg, nausea hit 42.4% (placebo 14.8%), diarrhea 32.0%, constipation 26.1% and vomiting 25.3%. Dysesthesia, an abnormal skin sensation, appeared in 12.5% at 12 mg versus 0.9% on placebo; it was mostly mild and usually resolved. Urinary tract infections ran modestly higher. In TRIUMPH-3, heart events were not significantly different from placebo (MACE-5 hazard ratio 0.82, 95% CI 0.55–1.22).

How dosing worked. Every participant started at 2 mg weekly and stepped up every four weeks. The highest dose tested was 12 mg. Each patient was screened, monitored and given drug from a single GMP-controlled supply with verified identity and potency.

What gray-market users report

People using gray-market retatrutide report less weight loss than trial participants, a different side-effect pattern, and the same heart-rate rise. Three independent data sources point the same way.

1. Reddit self-reports

University of Pennsylvania researchers used a language model to read 148,640 retatrutide posts and comments from 27 Reddit communities, May 2021 through December 2025. They identified 13,589 users reporting current use; 7,823 described at least one symptom (Sehgal et al., medRxiv, preprint).

That list is striking. On Reddit, increased hunger tops the list for a drug whose main effect is appetite suppression. The authors note this could reflect product quality and dose variability, stacking with other peptides, home reconstitution, or simply who posts on Reddit.

2. Electronic health records

This study searched clinical notes from a 29-million-patient U.S. records network and found 652 confirmed retatrutide users. Of those with a known source, 71.2% got it outside a trial: 57.4% from online or telehealth vendors, 29.4% from compounding pharmacies, and 8.7% from wellness or med-spa clinics (Murugadoss et al., Preprints.org, Aug 2026).

Trial participants seen in routine care lost 15.5% of body weight at 6–12 months, close to the TRIUMPH average. Gray-market users lost only 7.2%, no better than matched tirzepatide users. Yet both retatrutide groups showed the same heart-rate rise at 3 months (+4.3 and +2.5 bpm), which semaglutide and tirzepatide users did not. Pooled retatrutide users also had more new cardiovascular symptoms (rate ratio 1.56) and neuropsychiatric symptoms (1.95) than semaglutide users. Some clinic preparations mixed retatrutide with cagrilintide, BPC-157, NAD+ or IGF-1 analogues.

3. FDA adverse event reports

Public Citizen counted 10 retatrutide reports to FDA in 2025, four with hospitalization. In the first five months of 2026 there were 26, with 11 hospitalizations and three described as life-threatening (Public Citizen, June 2026). Reported cases include tachycardia, ketoacidosis, and one user diagnosed with acute necrotizing pancreatitis. One widely discussed case involved a self-administered dose of 40 mg, more than three times the highest dose ever tested (StationLM summary).

None of these sources can prove cause. Self-reports are biased toward people having problems, and the records study is observational and not yet peer reviewed. But they agree with each other, and they disagree with the trials in a consistent direction.

Side by side

Same molecule name, different experience: gray-market users appear to get about half the weight loss with the same cardiac stimulation and more unexplained symptoms.

Why the gap exists: it's the vial, not just the molecule

The most likely explanation for half the weight loss with the same side effects is simple: people are not injecting what the label says. The molecule may share a name; the product is not the same drug.

What independent testing finds

Finnrick, a consumer testing service, had tested 2,759 retatrutide samples by May 2026 and rated 71 of 179 vendors (39.6%) as poor, bad or fraud (Public Citizen). Individual vendor pages show the pattern:

In Australia, a vial bought online contained nearly double its labeled concentration (Hoodline, citing ABC). Most of these test reports list endotoxin as not tested.

Why "99% pure" didn't protect anyone

Notice the vials above reading 99%+ purity while missing up to 22% of their stated content. HPLC purity is the share of peptide-related signal that is the main peak. It does not measure how much peptide is actually in the vial, and it cannot confirm identity, sterility or endotoxin. Retatrutide is a 39-amino-acid peptide with non-natural residues and a fatty-acid side chain; closely related synthesis by-products can co-elute with the main peak. Only a validated method, run against a qualified reference standard, tells you what you are injecting.

So what is the real purity?

That is the question no gray-market COA answers. A purity number is only as good as the method behind it:

• Was the HPLC method qualified? A validated method must be shown to separate retatrutide from its likely by-products: deletion and insertion sequences, racemized residues, oxidized or deamidated forms, and incompletely lipidated chains. A generic gradient can bury those under the main peak and still print "99.8%."
• Against what reference standard? Only Lilly holds a fully characterized retatrutide standard. Testing labs in this market develop their own methods and standards; there is no method transfer from the manufacturer, so no one can show their number matches the true value.
• How much of the vial is peptide at all? HPLC purity is a relative number: it compares the main peak only to the other peptide-related peaks the detector sees. It says nothing about the rest of the vial's contents. Counter-ions, water, salts, solvents, metals, endotoxin and any non-peptide filler are invisible to it. A vial reading "99% pure" could be 10% peptide by weight and 90% everything else, and the purity number would not change.

The long-term worry: what else is being injected every week

Trial safety data describe Lilly's material only. Whatever else is in a gray-market vial has no safety data, and its effects may take years to appear, well beyond what Reddit posts or a 6-month records study can detect.

• Peptide-related impurities and immunogenicity. For generic synthetic peptides, FDA expects every peptide-related impurity at 0.10% or more to be identified, and any new impurity above 0.5% generally rules out the abbreviated pathway; between those levels the applicant must justify immunogenicity risk (FDA workshop slides; Pharmaceutical Online summary). Within the peptide fraction alone, a "99%" result can still mean 1% unidentified related impurities, twice that cap, and that is before counting anything HPLC cannot see. Because retatrutide is built on GIP, GLP-1 and glucagon-like sequences, antibodies raised against a modified impurity could in principle cross-react with the body's own hormones. That risk is theoretical and unstudied, which is the point.
• Residual TFA. Solid-phase synthesis and preparative HPLC use trifluoroacetic acid, and peptides come out as TFA salts unless deliberately exchanged. Approved peptide drugs control the counter-ion; gray-market powders rarely report it, and TFA can be a meaningful share of the powder's weight. Its safety for repeated weekly injection is not established.
• Residual solvents. Peptide synthesis and purification use solvents such as DMF, NMP, dichloromethane, acetonitrile and ether. ICH Q3C sets limits for these in medicines; gray-market COAs almost never test for them.
• Heavy metals. ICH Q3D governs elemental impurities from catalysts, equipment and reagents. In Australia, a researcher reported that testing of seized peptides found lead traces alongside vials of plain water and others at 190% of label (The Conversation Weekly, summary).
• Endotoxin and sterility. Most published vendor tests list endotoxin as not tested, and sterility is not tested at all.

Other reasons the experience differs

• Dose chaos. Under-filled vials explain weaker weight loss. Over-filled vials and self-escalation beyond 12 mg raise heart-rate and GI risk.
• Stacking. Many users combine retatrutide with other unapproved peptides, so symptoms cannot be assigned to any one product.
• Home reconstitution. Powder mixed at home adds contamination and measurement error that a ready-to-use GMP product does not have.
• No oversight. Nobody screens for contraindications, checks heart rate, or reports adverse events.
• Who posts. Reddit over-represents people with problems, and users differ from trial participants. But the records study matched users on age, sex, BMI and prior GLP-1 use, and the trial patients still lost twice as much.

The harm signal is growing

Exposures reported to America's Poison Centers averaged about 95 a month in January–April 2026, up 265% from late 2025 (Life Science Daily News, citing CBS). On August 12, 2026, Lilly sued six U.S. sellers, including a med spa and a compounding pharmacy, and reported more than 14,000 listings across 100+ countries. FDA's position is that retatrutide cannot be lawfully compounded, because it is not a component of any approved drug. That matters because 29.4% of gray-market users in the records study said they got it from a compounding pharmacy.

Bottom line

Retatrutide looks like a genuinely important medicine, and the gray market is not delivering it. Trial participants lose 20–28% of body weight under supervision with a verified product. Gray-market users, on current evidence, lose about what tirzepatide delivers, while taking on the heart-rate effect, extra symptoms, and the risk of a vial that is under-filled, over-filled or empty.

The legitimate paths are narrow but real: Lilly's clinical trials, Lilly's limited physician-requested early access for patients who meet medical criteria, and approved incretin medicines in the meantime. Lilly plans to file with FDA in Q1 2027. Until a product is approved, no pharmacy can lawfully compound retatrutide, and anyone offering it is operating outside the law.

If you are already using it, tell your clinician what you are taking and where it came from, and report problems to FDA MedWatch.

Sources

1. Lilly — TRIUMPH-1 topline results (May 21, 2026)
2. Lilly — TRIUMPH-2 and TRIUMPH-3 topline results (July 23, 2026)
3. Pharmaceutical Journal — TRIUMPH-1 and TRIUMPH-4 coverage
4. Jastreboff et al. — Phase 2 trial, NEJM 2023
5. Sehgal et al. — Self-reported side effects among Reddit users taking unapproved retatrutide, medRxiv 2026 (preprint)
6. Murugadoss et al. — Accelerating use of unapproved retatrutide is associated with weaker weight loss and increased cardiovascular symptoms, Preprints.org 2026 (preprint)
7. Public Citizen — The 'Miracle Drug' and the Peptide Craze Breaking the FDA (June 2026)
8. Life Science Daily News — Lilly sues six U.S. sellers (Aug 2026)
9. AJMC — 5 things to know about retatrutide (Aug 2026)
10. Finnrick — retatrutide test results, overseas trading company
11. Finnrick — retatrutide test results, U.S. seller
12. Hoodline — CBS investigation and ABC testing summary (July 2026)
13. StationLM — podcast summary of 40 mg self-dosing case
14. FDA — Peptide impurity profile and immunogenicity workshop slides (ANDA synthetic peptide guidance, May 2021)
15. Pharmaceutical Online — Peptides: regulatory and control strategies, impurities and immunogenicity
16. The Conversation Weekly — Peptide grey market episode summary